Since FOXM1 is upregulated and overexpressed in aggressive therapy-resistant forms of breast cancer and is associated with worse prognosis of patients [43,47], Api warrants further study as a potential treatment for endocrine-resistant BC. This evidence concerns the gene FOXM1 and breast cancer.